Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.…
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
Cadrenal Therapeutics (NASDAQ: CVKD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 1.700 USD on 20 November 2026, down 86.0% over 52 weeks. Its 52-week range is 0.8163 USD to 13.01 USD: the price is 86.9% below the high and 108.3% above the low.
Its market capitalisation is 7.01M USD.
Cadrenal Therapeutics reports return on equity of -483.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 3.06M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.